{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T13:42:35Z","timestamp":1793540555970,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MS is characterized by persistent central nervous system (CNS) inflammation. Investigating the CNS-compartmentalized inflammation associated with progressive MS could uncover new biomarkers and therapeutic targets. Cerebrospinal fluid (CSF) interleukin-6 (IL-6) can be markedly elevated in neuroinflammatory conditions, such as neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. This study investigated the association between CSF IL-6 levels, progressive disease, and disease severity in MS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Advanced technologies, including single-molecule arrays and microfluidics, were used to analyse CSF samples from individuals with MS at the time of diagnosis for IL-6. IL-6 levels were then correlated with clinical course, disease severity, and other known biomarkers associated with inflammation and disease severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Elevated IL-6 levels in the CSF were found in individuals with progressive MS, and CSF IL-6 showed positive correlations with the Expanded Disability Status Scale, the Multiple Sclerosis Severity Score, and CSF glial fibrillary acidic protein levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IL-6 in CSF indicates ongoing CNS inflammation and may contribute to the compartmentalized inflammation associated with disease progression and overall disease severity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-025-04145-0","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T17:55:39Z","timestamp":1743702939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Intrathecal interleukin-6 levels are associated with progressive disease and clinical severity in multiple sclerosis"],"prefix":"10.1186","volume":"25","author":[{"given":"Justine","family":"Itorralba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koroboshka","family":"Brand-Arzamendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Muccilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"4145_CR1","first-page":"a028936","volume":"8","author":"H Lassmann","year":"2018","unstructured":"Lassmann H. Multiple sclerosis pathology. Csh Perspect Med. 2018;8:a028936.","journal-title":"Csh Perspect Med"},{"key":"4145_CR2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162\u201373.","journal-title":"Lancet Neurol"},{"key":"4145_CR3","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1212\/NXI.0000000000000279","volume":"3","author":"SC Krieger","year":"2016","unstructured":"Krieger SC, Cook K, Nino SD, Fletcher M. The topographical model of multiple sclerosis: A dynamic visualization of disease course. Neurol - Neuroimmunol Neuroinflammation. 2016;3:e279.","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"key":"4145_CR4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann T, Moccia M, Coetzee T, Cohen JA, Correale J, Graves J, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023;22:78\u201388.","journal-title":"Lancet Neurol"},{"key":"4145_CR5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","volume":"14","author":"B Serafini","year":"2004","unstructured":"Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14:164\u201374.","journal-title":"Brain Pathol"},{"key":"4145_CR6","doi-asserted-by":"crossref","first-page":"607766","DOI":"10.3389\/fneur.2020.607766","volume":"11","author":"A Negron","year":"2020","unstructured":"Negron A, St\u00fcve O, Forsthuber TG. Ectopic lymphoid follicles in multiple sclerosis: centers for disease control?? Front Neurol. 2020;11:607766.","journal-title":"Front Neurol"},{"key":"4145_CR7","doi-asserted-by":"crossref","first-page":"e200052","DOI":"10.1212\/NXI.0000000000200052","volume":"10","author":"C Barro","year":"2022","unstructured":"Barro C, Healy BC, Liu Y, Saxena S, Paul A, Polgar-Turcsanyi M, et al. Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflammation. 2022;10:e200052.","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"4145_CR8","doi-asserted-by":"crossref","unstructured":"Meier S, Willemse EAJ, Schaedelin S, Oechtering J, Lorscheider J, Melie-Garcia L et al. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. Jama Neurol. 2023;80.","DOI":"10.1001\/jamaneurol.2022.5250"},{"key":"4145_CR9","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Group and the N. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology. Jama Neurol. 2019;76:1035\u201348.","journal-title":"Jama Neurol"},{"key":"4145_CR10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12974-023-02843-5","volume":"20","author":"T Liu","year":"2023","unstructured":"Liu T, Zuo H, Ma D, Song D, Zhao Y, Cheng O. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer\u2019s disease-associated biomarkers alterations among de Novo Parkinson\u2019s disease patients: a prospective cohort study. J Neuroinflammation. 2023;20:167.","journal-title":"J Neuroinflammation"},{"key":"4145_CR11","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3389\/fnins.2019.01026","volume":"13","author":"Z Bai","year":"2019","unstructured":"Bai Z, Chen D, Wang L, Zhao Y, Liu T, Yu Y, et al. Cerebrospinal fluid and blood cytokines as biomarkers for multiple sclerosis: A systematic review and Meta-Analysis of 226 studies with 13,526 multiple sclerosis patients. Front Neurosci-switz. 2019;13:1026.","journal-title":"Front Neurosci-switz"},{"key":"4145_CR12","doi-asserted-by":"crossref","unstructured":"Martin S-J, Brand-Arzamendi K, Saab G, Muccilli A, Oh J, Schneider R. GM-CSF is a marker of compartmentalised intrathecal inflammation in multiple sclerosis. Mult Scler (Houndmills, Basingstoke, Engl). 2023;:13524585231195860.","DOI":"10.1177\/13524585231195861"},{"key":"4145_CR13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clinbiochem.2013.12.024","volume":"47","author":"CE Teunissen","year":"2014","unstructured":"Teunissen CE, Tumani H, Engelborghs S, Mollenhauer B. Biobanking of CSF: international standardization to optimize biomarker development. Clin Biochem. 2014;47:288\u201392.","journal-title":"Clin Biochem"},{"key":"4145_CR14","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444\u20131444.","journal-title":"Neurology"},{"key":"4145_CR15","first-page":"1144","volume":"64","author":"RHSR Roxburgh","year":"2005","unstructured":"Roxburgh RHSR, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, et al. Multiple Scler Severity Score Neurol. 2005;64:1144\u201351.","journal-title":"Multiple Scler Severity Score Neurol"},{"key":"4145_CR16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(96)00283-3","volume":"146","author":"D Maimone","year":"1997","unstructured":"Maimone D, Guazzi GC, Annunziata P. IL-6 detection in multiple sclerosis brain. J Neurol Sci. 1997;146:59\u201365.","journal-title":"J Neurol Sci"},{"key":"4145_CR17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/imm.13395","volume":"164","author":"J Zhan","year":"2021","unstructured":"Zhan J, Kipp M, Han W, Kaddatz H. Ectopic lymphoid follicles in progressive multiple sclerosis: from patients to animal models. Immunology. 2021;164:450\u201366.","journal-title":"Immunology"},{"key":"4145_CR18","doi-asserted-by":"crossref","first-page":"104789","DOI":"10.1016\/j.ebiom.2023.104789","volume":"96","author":"H Touil","year":"2023","unstructured":"Touil H, Li R, Zuroff L, Moore CS, Healy L, Cignarella F, et al. Cross-talk between B cells, microglia and macrophages, and implications to central nervous system compartmentalized inflammation and progressive multiple sclerosis. eBioMedicine. 2023;96:104789.","journal-title":"eBioMedicine"},{"key":"4145_CR19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fncel.2020.00120","volume":"14","author":"MS Bassi","year":"2020","unstructured":"Bassi MS, Iezzi E, Drulovic J, Pekmezovic T, Gilio L, Furlan R, et al. IL-6 in the cerebrospinal fluid signals disease activity in multiple sclerosis. Front Cell Neurosci. 2020;14:120.","journal-title":"Front Cell Neurosci"},{"key":"4145_CR20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cca.2013.03.020","volume":"421","author":"A Uzawa","year":"2013","unstructured":"Uzawa A, Mori M, Sawai S, Masuda S, Muto M, Uchida T, et al. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis Optica attacks. Clin Chim Acta. 2013;421:181\u20133.","journal-title":"Clin Chim Acta"},{"key":"4145_CR21","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/cei.12733","volume":"183","author":"PO Barros","year":"2016","unstructured":"Barros PO, Cassano T, Hygino J, Ferreira TB, Centuri\u00e3o N, Kasahara TM, et al. Prediction of disease severity in neuromyelitis Optica by the levels of Interleukin (IL)-6 produced during remission phase. Clin Exp Immunol. 2016;183:480\u20139.","journal-title":"Clin Exp Immunol"},{"key":"4145_CR22","doi-asserted-by":"crossref","unstructured":"Uzawa A, Mori M, Masuda H, Muto M, Ohtani R, Aoyama S, et al. Contributions of CSF interleukin-6 elevation to the pathogenesis of Myelin oligodendrocyte glycoprotein antibody-associated disease. Mult Scler (Houndmills Basingstoke Engl). 2024. 13524585241254732.","DOI":"10.1177\/13524585241254731"},{"key":"4145_CR23","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. Trial of satralizumab in neuromyelitis Optica spectrum disorder. N Engl J Med. 2019;381:2114\u201324.","journal-title":"N Engl J Med"},{"key":"4145_CR24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","volume":"19","author":"C Zhang","year":"2020","unstructured":"Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, et al. Safety and efficacy of Tocilizumab versus azathioprine in highly relapsing neuromyelitis Optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19:391\u2013401.","journal-title":"Lancet Neurol"},{"key":"4145_CR25","doi-asserted-by":"crossref","first-page":"e200266","DOI":"10.1212\/NXI.0000000000200266","volume":"11","author":"R Akatani","year":"2024","unstructured":"Akatani R, Chihara N, Hara A, Tsuji A, Koto S, Kobayashi K, et al. Interleukin-6 signaling Blockade induces regulatory plasmablasts in neuromyelitis Optica spectrum disorder. Neurol Neuroimmunol Neuroinflammation. 2024;11:e200266.","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"4145_CR26","doi-asserted-by":"crossref","first-page":"e200243","DOI":"10.1212\/NXI.0000000000200243","volume":"11","author":"A Virupakshaiah","year":"2024","unstructured":"Virupakshaiah A, Moseley CE, Elicegui S, Gerwitz LM, Spencer CM, George E, et al. Life-Threatening MOG Antibody-Associated hemorrhagic ADEM with elevated CSF IL-6. Neurol Neuroimmunol Neuroinflammation. 2024;11:e200243.","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"4145_CR27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/1352458515623862","volume":"22","author":"P Beauchemin","year":"2015","unstructured":"Beauchemin P, Carruthers R. MS arising during Tocilizumab therapy for rheumatoid arthritis. Mult Scler J. 2015;22:254\u20136.","journal-title":"Mult Scler J"},{"key":"4145_CR28","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","volume":"23","author":"S Rose-John","year":"2023","unstructured":"Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller J. Targeting IL-6 trans-signalling: past, present and future prospects. Nat Rev Immunol. 2023;23:666\u201381.","journal-title":"Nat Rev Immunol"},{"key":"4145_CR29","first-page":"504","volume":"11","author":"AJ Devasahayam","year":"2021","unstructured":"Devasahayam AJ, Kelly LP, Williams JB, Moore CS, Ploughman M. Fitness shifts the balance of BDNF and IL-6 from inflammation to repair among people with progressive multiple sclerosis. Biomol. 2021;11:504.","journal-title":"Biomol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04145-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04145-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04145-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:03:16Z","timestamp":1743724996000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04145-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4145"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04145-0","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Unity Health Toronto\u2019s Research Ethics Board. Before enrolment, written informed consent was obtained from all participants or their legal guardians. The study was conducted according to Unity Health Toronto\u2019s ethical standards and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants provided written informed consent for the publication of anonymized data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Justine Itorralba has nothing to disclose. Ms. Koroboshka Brand-Arzamendi has nothing to disclose. Dr. Georges Saab has received payment or honoraria for presentations, lectures, or educational events from EMD-Serono. Dr. Saab has received funding for international conference attendance from EMD-Serono. Dr Saab received support to attend a scientific meeting and advisory board from EMD-Serono and Hoffman-La Roche. Dr. Alexandra Muccilli has received payment or honoraria for lectures, presentations, speakers\u2019 bureaus and other educational initiatives from Biogen-Idec, EMD-Serono and Novartis. Dr. Raphael Schneider received grants from the MS Society of Canada and the J.P. Bickell Foundation. Dr. Schneider has received consulting fees from Biogen-Idec and Novartis. Dr. Schneider has received payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing or educational events from Biogen-Idec, Sanofi-Genzyme, and EMD-Serono. Dr. Schneider has participated on advisory boards for Novartis and BMS. Dr. Schneider has received support for attending a scientific meeting from EMD-Serono.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"136"}}